CoChat

γδ T cells in cancer immunotherapy

Open access
Zou, Chang, Zhao, Pan, Xiao, Zhangang, Han, Xianghua, Fu, Fan, Fu, Li · 2017 · Oncotarget
Cited by 93

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Chang Zou 1,* , Pan Zhao 2,* , Zhangang Xiao 3,* , Xianghua Han 2 , Fan Fu 2 and Li Fu 4 1 Clinical Medical Research Center, The Second Clinical College of Jinan University, Shenzhen People’s Hospital, Shenzhen, China 2 Research Institute of Shenzhen Hornetcorn biotechnology, Shenzhen, China 3 Department of Pharmacology, Laboratory of Molecular Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, PR China 4. Department of Pharmacology, Shenzhen Key Laboratory of translational Medicine of Tumor and Cancer Research Centre, School of Medicine, Shenzhen University, Shenzhen, China * These authors have contributed equally to this work Correspondence to: Chang Zou, email: // Li Fu, email: // Keywords : γδ T cells, immunotherapy, anti-tumor, cancer treatment Received : August 05, 2016 Accepted : October 27, 2016 Published : November 03, 2016 Abstract γδ T cells are one of the three immune cell types that express antigen receptors. They contribute to lymphoid antitumor surveillance and bridge the gap between innate and adaptive immunity. γδ T cells have the capacity of secreting abundant cytokines and exerting potent cytotoxicity against a wide range of cancer cells. γδ T cells exhibit important roles in immune-surveillance and immune defense against tumors and have become attractive effector cells for cancer immunotherapy. γδ T cells mediate anti-tumor therapy mainly by secreting pro-apoptotic molecules and inflammatory cytokines, or through a TCR-dependent pathway. Recently, γδ T cells are making their way into clinical trials. Some clinical trials demonstrated that γδ T cell-based immunotherapy is well tolerated and efficient. Despite the advantages that could be exploited, there are obstacles have to be addressed for the development of γδ T cell immunotherapies. Future direction for immunotherapy using γδ T cells should focus on overcoming the side effects of γδ T cells and exploring better antigens that help stimulating γδ T cell expansion in vitro .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.13051

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Zou, C., Zhao, P., Xiao, Z., Han, X., Fu, F., & Fu, L.
Venue
Oncotarget
Published
2016-11-03
Volume
8
Issue
5
Pages
8900-8909
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2546649885
Cited by
93
References
3
FWCI
5.89
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.